Video information: At the 2017 ASCO meeting in Chicago, Dr. George Simon and Dr. David Carbone talk about news and progress in small cell lung cancer. Dr. Simon goes into detail on some new promising approaches and current studies for small cell lung cancer treatment, adding "these are some of the newer, in my opinion, more exciting approaches...
Read MoreIn a nutshell This study examined the order of treatment with ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (ABT-199) for chronic lymphocytic leukemia (CLL). Researchers concluded that ibrutinib appears superior to idelalisib as first treatment. Some background Early studies are reporting promising results with targeted therapies for...
Read More
In a nutshell This study investigated the effectiveness of the chemotherapy FOLFOX plus cetuximab (Erbitux), after cancer progression with FOLFIRI plus cetuximab. Researchers suggested that FOLFOX plus cetuximab is an important treatment option in non-KRAS mutated metastatic (spread to other parts of the body) colorectal cancer. Some background...
Read More
In a nutshell This study compared the rates of peripheral arterial occlusive disease (PAOD) in chronic myeloid leukemia (CML) patients treated with different therapies. The authors concluded that nilotinib (Tasigna) was associated with higher rates of PAOD than other treatments. Some background Tyrosine kinase inhibitors (TKIs) are now the...
Read More
In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...
Read More
In a nutshell This study investigated the role of trastuzumab (Herceptin) as part of standard care in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC). The study conclude that trastuzumab was effective in general practice, including patients not often included in clinical trials (such as the...
Read More
In a nutshell This study investigated how the early development of a rash in treatment with lapatinib (Tykerb) impacts survival outcomes in breast cancer. This study concluded that early development of rash may indicate the patients who will benefit more from lapatinib. Some background Lapatinib is a drug which targets epidermal...
Read More
In a nutshell This study investigated predictors of response to therapy in patients with HER2-positive advanced breast cancer. The study concluded that mucocutaneous toxicities (those affecting the skin or mucous membranes) could be predictors of the response to lapatinib (Tykerb or Tyverb) in patients with HER2-positive advanced breast...
Read More
In a nutshell This study investigated the rate and outcome of trastuzumab (Herceptin) associated cardiac (heart) dysfunction in patients after 1 or 2 years of therapy. The study concluded that for patients treated with adjuvant trastuzamab, the occurrence of cardiac events remained low and that these cardiac events were mostly reversible after...
Read More
In a nutshell This study focused on the effectiveness of bevacizumab (Avastin) in the treatment of metastatic colorectal cancer. Some background Colorectal cancer is any cancer that involves the colon, rectum, or both. It has a tendency to spread to other organs, frequently the liver. This phenomenon is called metastatic colorectal cancer....
Read More
In a nutshell This meta-analysis examined the risk of fatal adverse events among various advanced cancer patients receiving EGFR-targeting monoclonal antibodies. Some background A mutation causing the overproduction (termed overexpression) of epidermal growth factor receptor (EGFR), which plays a role in the creation, migration, and survival of...
Read More
In a nutshell This study examined whether there is an increased risk of hypertension among cancer patients being treated with regorafenib (Stivarga). Some background Vascular endothelial growth factor receptors (VEGF-r) are complexes on the surface of cells which stimulate the growth of new blood vessels, and are crucial for cancer growth and...
Read More
